Genetic and Clinical Features in TP53-Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next-Generation Sequencing Data
{{output}}
Background: The recent fifth edition of World Health Organization and International Consensus Classification in 2022 recognized TP53-mutated myelodysplastic neoplasms (MDS) as a distinct entity requiring multi-hit classification.... ...
